Home > Insider Trading > Filing (0001104659-14-009543)

Filing Details

Accession Number:: 0001104659-14-009543
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-02-13 10:53:02
Reporting Period:: 2014-02-11

Filing Date:: 2014-02-13
Accepted Time:: 2014-02-13 10:53:02
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1586105	Egalet Corp	EGLT	Pharmaceutical Preparations (2834)	463575334

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1528382	Omega Fund Iv, L.p.	1 Royal Plaza, Royal Avenue St. Peter Port Y7 GY1 2HL		No	No	Yes	No
1591226	P/S I Spv Biotech Danish	1 Royal Plaza, Royal Avenue St. Peter Port Y7 GY1 2HL		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-02-11	438,364	$0.00	438,364	No	4	C	Direct
Common Stock	Acquisiton	2014-02-11	251,125	$0.00	689,489	No	4	C	Direct
Common Stock	Acquisiton	2014-02-11	523,799	$0.00	1,213,288	No	4	C	Direct
Common Stock	Acquisiton	2014-02-11	112,500	$0.00	1,325,788	No	4	X	Direct
Common Stock	Acquisiton	2014-02-11	213,136	$6.00	1,538,924	No	4	C	Direct
Common Stock	Acquisiton	2014-02-11	321,077	$6.00	1,860,001	No	4	C	Direct
Common Stock	Acquisiton	2014-02-11	156,250	$12.00	2,016,251	No	4	P	Direct
Common Stock	Acquisiton	2014-02-11	60,000	$0.00	60,000	No	4	X	Direct
Common Stock	Acquisiton	2014-02-11	171,241	$6.00	231,241	No	4	C	Direct
Common Stock	Acquisiton	2014-02-11	83,333	$12.00	314,574	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	X	Direct
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct
No	4	X	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1 Preferred Stock	Disposition	2014-02-11	438,364	$0.00	438,364	$0.00
Common Stock	Series A-2 Preferred Stock	Disposition	2014-02-11	251,125	$0.00	251,125	$0.00
Common Stock	Series B Preferred Stock	Disposition	2014-02-11	523,799	$0.00	523,799	$0.00
Common Stock	Warrants	Disposition	2014-02-11	112,500	$0.00	112,500	$0.00
Common Stock	Subordinated Convertible Debt	Disposition	2014-02-11	0	$0.00	213,136	$6.00
Common Stock	Senior Convertible Debt	Disposition	2014-02-11	0	$0.00	321,077	$6.00
Common Stock	Warrants	Disposition	2014-02-11	60,000	$0.00	60,000	$0.00
Common Stock	Senior Convertible Debt	Disposition	2014-02-11	0	$0.00	171,241	$6.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	X	Direct
No	4	C	Direct
No	4	C	Direct
No	4	X	Direct
No	4	C	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	314,732	Indirect	By Egalet A/S

Footnotes

These securities are owned by Danish Biotech SPV I P/S ("Danish Biotech"), who is a member of a "group" with Omega Fund IV L.P. ("Omega") for purposes of Section 13(d) of the Exchange Act. This Form 4 is being filed jointly by Danish Biotech and Omega in connection with the consummation of Egalet Corporation's initial public offering. The address of Omega is 1 Royal Plaza, Royal Avenue, St. Peter Port, Guernsey, GY1 2HL.
The reporting person is Egalet A/S, a corporation. Danish Biotech is a 24.4% equityholder of Egalet A/S.
The Series A-1 Preferred Stock automatically converted into Egalet Corporation common stock on a 1-for-1 basis immediately prior to the consummation of Egalet Corporation's initial public offering.
The Series B Preferred Stock automatically converted into Egalet Corporation common stock on a 1-for-1 basis immediately prior to the consummation of Egalet Corporation's initial public offering.
The warrants were automatically exercised into Egalet Corporation common stock immediately prior to the consummation of the Egalet Corporation's initial public offering on a 1-for-1 basis, pursuant to the securityholders' purchase of a specified minimum amount of common stock in such offering.
The subordinated convertible debt automatically converted into Egalet Corporation common stock immediately prior to the consummation of Egalet Corporation's initial public offering, based on a conversion price equal to 50% of the per share price in such offering, which was $12 per share.
The senior convertible debt automatically converted into Egalet Corporation common stock immediately prior to the consummation of Egalet Corporation's initial public offering, based on a conversion price equal to 50% of the per share price in such offering, which was $12 per share.
These securities are owned by Omega, who is a member of a "group" with Danish Biotech for purposes of Section 13(d) of the Exchange Act. This Form 4 is being filed jointly by Danish Biotech and Omega in connection with the consummation of Egalet Corporation's initial public offering.
The Series A-2 Preferred Stock automatically converted into Egalet Corporation common stock on a 1-for-1 basis immediately prior to the consummation of Egalet Corporation's initial public offering.